Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3066637 | 1.00 | CTSS (0.59) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL22730085 | 1.00 | CTSS (0.59) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL29559326 | 1.00 | CTSS (0.59) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL25524204 | 0.95 | CTSS (0.53) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL13090480 | 0.93 | CTSS (0.60) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL16588660 | 0.93 | CTSS (0.68) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL22484282 | 0.91 | CTSS (0.52) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL13090510 | 0.91 | CTSS (0.59) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL13090488 | 0.91 | CTSS (0.48) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL3069901 | 0.90 | CTSS (0.55) | CTSSADRB3ADRA2BADRA2CCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-03-03 | — | — | US | disclosed |
| US-12559530-B2 | Regulated synthetic gene expression systems | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-02-24 | — | — | US | disclosed |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250243247-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-07-31 | — | — | US | disclosed |
| EP-3471737-B1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250059243-A1 | REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250057837-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-12202863-B2 | Chimeric antigen receptor (CAR) modulation | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-01-21 | — | — | US | disclosed |
| EP-2970357-B1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-12180485-B2 | Repressible control of gene expression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-12-31 | — | — | US | disclosed |
| CN-115427439-A | Protease switches for dual target chimeric antigen receptor T cell therapy | 德克萨斯A&M大学系统 | 2022-12-02 | — | — | CN | disclosed |
| US-11484534-B2 | Methods for treating HCV | ABBVIE INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-11485753-B2 | Substituted nucleosides, nucleotides and analogs thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-01 | — | — | US | disclosed |
| US-11472826-B2 | Acyclic antivirals | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-18 | — | — | US | disclosed |
| US-11453893-B2 | RNA-based delivery systems with levels of control | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220288153-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4051701-A1 | PROTEASE SWITCH FOR DUAL TARGETS CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | The Texas A&M University System (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11419904-B2 | Immunomodulatory compositions and methods of use thereof | AGRAWAL BABITA (CA) | 2022-08-23 | — | — | US | disclosed |
| EP-2909209-B1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | PNP, DUT, TYMP | CTSS 1985/4885ADRB3 3441/4885ADRA2B 3605/4885 |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | CTSS 31/4885ADRB3 1820/4885ADRA2B 2724/4885 |
| US-11485753-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C2 | CTSS 2963/4885ADRB3 2905/4885ADRA2B 2765/4885 |
| US-20220288153-A1 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | CTSS 1105/4885ADRB3 2333/4885ADRA2B 1515/4885 |
| US-20250057837-A1 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | CTSS 1038/4885ADRB3 2147/4885ADRA2B 1384/4885 |
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | ADAR, ADA, NSUN2 | CTSS 4768/4885ADRB3 3872/4885ADRA2B 3039/4885 |
| US-20250059243-A1 | REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS | BPTF, SRRT, TEAD3 | CTSS 2036/4885ADRB3 4752/4885ADRA2B 4726/4885 |
| US-20250243247-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | CTSS 53/4885ADRB3 3737/4885ADRA2B 3371/4885 |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | CTSS 53/4885ADRB3 3737/4885ADRA2B 3371/4885 |
| US-11484534-B2 | Methods for treating HCV | EIF2AK2, IFNAR1, IFNG | CTSS 1038/4885ADRB3 2147/4885ADRA2B 1384/4885 |
| US-12202863-B2 | Chimeric antigen receptor (CAR) modulation | HAVCR2, CPB1, CTRL | CTSS 53/4885ADRB3 3737/4885ADRA2B 3371/4885 |
| US-12559530-B2 | Regulated synthetic gene expression systems | MECP2, ZMYND8, EED | CTSS 2631/4885ADRB3 3229/4885ADRA2B 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.